The anti-CCR4 antibody mogamulizumab has antitumor activity against cutaneous T-cell lymphoma by antibody-dependent cell killing [121], and has been already applied in a clinical setting. Here, CCR4 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.